Key Takeaways
- H1 revenue surged 43% YoY to ₹214.41 crores, fueled by defense and aerospace dominance and new Tier-1 customer wins in commercial aerospace and industrial electronics.
- Order book of ₹1,062 crores provides 18–24 months of visibility, anchoring management's confidence in sustaining 30%–35% annual growth over the next 3–4 years.
- NADCAP AC7120 accreditation unlocks a global competitive moat, placing Vinyas among a select group of manufacturers qualified for regulated commercial aerospace and export-controlled defense programs.
- Capacity doubling is underway but 18 months out: current capacity supports ₹1,100–₹1,200 crores in revenue, with new CAPEX-funded lines expected online post-March 2027.
- What to watch next quarter: progress on capacity utilization toward the 50%–55% year-end target, any new program disclosures once first-article inspections clear, and the pace of vertical diversification away from the 70%–75% defense concentration.
Growth Engine & Order Book
- 43% YoY H1 growth driven by defense and aerospace as the largest contributors, onboarding of new Tier-1 customers in commercial aerospace and industrial electronics, and steady progress in medical electronics.
- Order book stands at ₹1,062 crores, a mix of short-term and long-term orders with the longest stretching 18–24 months, giving clear multi-year visibility.
- 30%–35% annual growth target for the next 3–4 years, with management expecting no fluctuation and confidence the order book will be sufficient to fuel it.
- Order intake discipline: internal target is to keep order intake aligned with revenue targets, ensuring the order book always covers 24 months of requirements factoring in growth.
- Pipeline rests on five drivers: existing defense business, system integration work, vertical expansion, technology transfers expected over the short and medium term, and the PCBA business remaining the major portion while system integration grows over 3–4 years.
- Defense lumpiness is being mitigated by adding more programs within defense and aerospace and diversifying vertically into industrial, medical devices (target 10% of revenue), commercial aerospace, and railways.
Sumukh Narendra: "Each of the programs have generally a gestation period of 24-36 months to mature to a level of series production as well as there is the qualification from the foreign OEMs as well as the domestic public sector undertakings and the private players which is a significantly high entry barrier segment."
NADCAP Accreditation & Competitive Moat
- NADCAP AC7120 accreditation achieved for electronics in printed board assemblies, a process-level audit covering traceability and process adherence across every aspect of manufacturing that took roughly two years to secure.
- Very few companies in India are NADCAP accredited, and the list of certified companies is available to all subscribing OEMs globally, making it materially easier to start discussions with larger OEMs that otherwise would not entertain Vinyas for certain programs.
- Certification required digitization of the plant to ensure traceability for every process; the facility is now approximately 80%–85% digital with a target to reach 95%+ over the next year.
- Unlocks regulated commercial aerospace and export-controlled defense programs, positioning Vinyas among a select group of electronics manufacturers worldwide meeting stringent aerospace quality requirements.
Sumukh Narendra: "NADCAP is globally regarded as the highest benchmark for aerospace manufacturing quality. Achieving this accreditation places Vinyas among a very select group of electronics manufacturers worldwide that meet the stringent requirement."
Capacity Expansion & Utilization
- Current operational capacity can support ₹1,100–₹1,200 crores in revenue; the ongoing CAPEX round, with ₹30 crores earmarked from the ₹150 crore capital raise, will double that capacity.
- New capacity comes online post-March 2027, an 18-month timeline driven by the need to get new SMT lines and testing/quality inspection equipment fully qualified and approved by existing customers.
- Utilization ramp targets: reach at least 50%–55%–60% capacity utilization by the end of this fiscal year, and 70%–75% by the end of next year.
- Capital raise of ₹150.04 crores completed, with the first tranche of ~₹61 crores received in September 2025, strengthening the balance sheet for working capital, capacity expansion, and administrative expenses.
Sumukh Narendra: "I think we should reach about 55%-60% capacity utilization, 50% at least by the end of this year and reach about 70%-75% utilization by end of next year."
Margins & Working Capital
- H1 EBITDA margin at 11.15%, with margins varying by program mix and expected to remain in the 9%–11% range.
- Lower gross margin mix in H1 was a function of the specific programs executed during the period; management is working toward improving the mix with higher gross margin programs to lift EBITDA margin.
- Internal target to achieve at least 3 basis points uptake on EBITDA margin over approximately 4 years.
- Inventory has risen because the monthly revenue tranche has also risen; inventory stands at about 2 months of revenue.
- Receivables marginally reduced compared to last March; the endeavor is to keep reducing them, and if revenue lumpiness can be managed, receivable days should fall below 4 months.
- Customer advances have started coming in, and working capital requirements for the next 3 years are expected to be more than sufficient from the capital raise.
Vertical Diversification & Business Model
- Revenue mix is 70%–75% defense and aerospace, approximately 15% industrial electronics, with the balance in medical and other segments; the order book carries an even larger defense portion since industrial and medical work on shorter conversion cycles with rotation.
- 5-year diversification target: reduce defense and aerospace to approximately 60% of revenue, with four other segments (industrial, medical devices, commercial aerospace, railways) contributing approximately 40%.
- Medical devices target is 10% of revenue, and the company is working toward build-to-spec capabilities in commercial, industrial, and medical verticals.
- Business model is primarily build-to-print: customers provide specifications and Vinyas builds as per print; the company does not own IP. On defense and aerospace, there is no short-term intention to explore build-to-spec, with the focus first on building capabilities in other verticals.
- Customer mix is an equal split among defense PSUs, private sector players in India, and foreign OEMs; Vinyas can act as a Tier-1 supplier in India, working directly with OEMs or directly with the public sector.
- Supply chain is diversified, sourcing from Southeast Asia, the US, Europe, Israel, and domestically; on the defense and aerospace side, procurement is limited by non-import of material from China, and some made-to-order parts carry single-supplier dependencies that are part of the defense business.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Sustain 30%–35% YoY growth every year | Next 3–4 years |
| EBITDA margin uplift | At least 3 bps uptake from current levels | Approximately 4 years |
| Capacity utilization | Reach 50%–55%–60% | By end of this fiscal year |
| Capacity utilization | Reach 70%–75% | By end of next fiscal year |
| New capacity online | Current CAPEX round doubles capacity | Post-March 2027 (18 months) |
| Digitization | Reach 95%+ facility digitization | Next 1 year |
| Vertical mix | Reduce defense/aerospace to ~60% of revenue | 5 years |
| Medical devices | Reach 10% of revenue | Implied within 5-year diversification window |
| Order book coverage | Maintain order book sufficient for 24 months of requirements | Ongoing discipline |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| H1 FY26 revenue | ₹214.41 cr, +43% YoY |
| H1 FY26 EBITDA | ₹23.90 cr, margin 11.15% |
| H1 FY26 PAT | ₹9.35 cr, +33% YoY |
| FY26 revenue growth guidance | 30–35% YoY, expected to sustain for next 3–4 years |
| EBITDA margin guidance | 9–11%, internal target to improve by 3 bps over ~4 years |
| H1 FY26 order inflow | ₹411 cr |
| Order book | ₹1,062 cr as of 30 Sep 2025, to be executed over 18–24 months |
| Revenue mix: defense & aerospace | 70–75% of H1 FY26 revenue |
| Revenue mix: industrial electronics | ~15% of H1 FY26 revenue |
| Capital raise | ₹150.04 cr, first tranche of ~₹61 cr received in Sep 2025 |
| CAPEX from capital raise | ₹30 cr earmarked |
| CWIP | ₹21.06 cr |
| Current revenue capacity | ₹1,100–1,200 cr, current CAPEX round to double capacity |
| Capacity utilization target | 50–60% by end of FY26, 70–75% by end of FY27 |
| New capacity operational timeline | Post-March 2027, ~18 months from now |
| Inventory | ~2 months of revenue |
| Receivable days target | Under 4 months |
| Manufacturing digitization | 80–85% digital, target 95%+ in next 1 year |
| 5-year revenue diversification target | Defense & aerospace to ~60%, other 4 segments to ~40% |
| Medical devices revenue target | ~10% of revenue |